IMUC.US ImmunoCellular Therapeutics Ltd

Healthcare Biotechnology USA Stocks
0.1580 USD
Close of Nov 15, 2026
0.0510 0.2700
Market cap
USD 20.0M
P/E
0.1x
P/B
0.35x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is IMUC.US undervalued?

Graham number

The Graham number of ImmunoCellular Therapeutics Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ImmunoCellular Therapeutics Ltd fundamental analysis

No fundamental analysis for ImmunoCellular Therapeutics Ltd yet.

ImmunoCellular Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ImmunoCellular Therapeutics Ltd

EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer…

Full company profile